Publicaciones en colaboración con investigadores/as de Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias (18)

2024

  1. SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2771-2782

2023

  1. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2021

  1. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

    Clinical and Translational Oncology, Vol. 21, Núm. 9, pp. 1270-1279

2018

  1. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

    Therapeutic Advances in Medical Oncology, Vol. 10

  2. The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 230-242

2017

  1. Chronic opioid therapy in long-term cancer survivors

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 236-250

  2. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study

    European Respiratory Journal, Vol. 49, Núm. 1

  3. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768

  4. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395

  5. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: The EPIPHANY Index

    British Journal of Cancer, Vol. 116, Núm. 8, pp. 994-1001

  6. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

    Gastric Cancer, Vol. 20, Núm. 3, pp. 465-474

  7. Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study

    European Journal of Radiology, Vol. 87, pp. 66-75

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

  2. GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases

    Annals of Oncology, Vol. 27, pp. vi383

  3. On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism

    Thrombosis Research, Vol. 143, pp. 76-85

  4. Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02

    Annals of Oncology, Vol. 27, pp. vi377